Oramed reaches 50% enrolment in Phase III trial of insulin capsule
The ORA-D-013-2 trial is enrolling 450 type 2 diabetes patients with insufficient glycemic control.

The ORA-D-013-2 trial is enrolling 450 type 2 diabetes patients with insufficient glycemic control.
The clinical trial of Allocetra will commence with two cohorts of intra-patient and intra-cohort dose escalation.
The trial will analyse the safety, tolerability, PK, anti-tumour activity and exploratory biomarkers for BND-22 activity.
Beaconcure’s platform Verify is designed to review clinical trial datasets and pinpoint inconsistencies.
ByNeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial to…
ByThe company anticipates reporting topline data from the trial in the second half of this year.
The trial will recruit 140 patients with biopsy-confirmed NASH.
J&J’s booster given after Pfizer-BioNTech’s two-dose regimen led to a continued rise of antibodies for a minimum of four weeks.
Thank you for subscribing to Clinical Trials Arena